NCT04439578已完成1 期
A Single-centre, Open, Single-dose, Self-control Study to Investigate the Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Chinese Adult Subjects.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Pharmacokinetics parameter: Cmax of SHR6390
研究概览
简要总结
The primary objective of the study is to evaluate the effect of rifampicin on pharmacokinetics of healthy Chinese adult subjects after oral administration of SHR6390 tablets. The secondary objective of the study is to evaluate the safety of SHR6390 alone and when co-administered with rifampicin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions;
- •Ability to complete the study as required by the protocol;
- •Healthy male or female subjects aged 18 to 45 (including 18 and 45) at the date of signing the informed consent;
- •Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and body mass index (BMI) within the range of 19 ~ 26 kg /m2 (including 19 and 26);
- •Subjects shall ake effective contraceptive measures voluntarily within 3 months from the date of signing the informed consent form to the date of the last medication. Serum HCG test of fertile women before the study must be negative
- •Physical examination (vital signs, physical examination), routine laboratory examination (blood routine, blood biochemistry, urine routine, coagulation function), 12-lead electrocardiogram, orthotopic chest X-ray and abdominal B-ultrasound are normal or abnormal but have no clinical significance
排除标准
- •Allergic constitution;
- •History of drug use, or drug abuse screening positive;
- •Alcoholic or often drinkers;
- •Left ventricular ejection fraction (LVEF) <50% by echocardiography;
- •A clear medical history of important primary organ diseases such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and musculoskeletal system.
- •Abnormal clinical laboratory tests and clinical significance judged by the investigator or other clinical findings showing the following diseases, including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases.
- •Participated in blood donation with blood donation volume ≥400 mL or received blood transfusion within 3 months before screening.
- •Patients who have had any surgery and taken hepatotoxic drugs in the previous 6 months before screening.
- •Patients who use any vitamin product or herb 14 days prior to screening.
- •HCV positive, HIV antibody positive, HBsAg positive, syphilis antibody positive.
- •Subjects who are considered unfit to participate in the study by the investigator
研究组 & 干预措施
Treatment
Experimental
subjects receiving a single oral dose of SHR6390 tablets, then rifampicin capsules 600 mg/day orally with a single oral dose of SHR6390 tablets co-administered.
干预措施: SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin (Drug)
结局指标
主要结局
Pharmacokinetics parameter: Cmax of SHR6390
时间窗: through study completion, an average of 32 days
Peak Plasma Concentration (Cmax) of SHR6390
Pharmacokinetics parameter: AUC of SHR6390
时间窗: through study completion, an average of 32 days
Area under the plasma concentration versus time curve (AUC) of SHR6390
次要结局
- Pharmacokinetics parameter: Tmax of SHR6390(:through study completion, an average of 32 days)
- Pharmacokinetics parameter: T1/2 of SHR6390(through study completion, an average of 32 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy SubjectsAdvanced Solid TumorNCT06198556Jiangsu HengRui Medicine Co., Ltd.18
已完成
1 期
A Rifampin Effect Study of SHR2554 on Healthy Chinese Adult SubjectsHealthyNCT04577885Jiangsu HengRui Medicine Co., Ltd.18
已完成
1 期
A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the BloodHealthyNCT04060719Boehringer Ingelheim16
已完成
1 期
To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)Pharmacokinetics of Darexaban and MetabolitesHealthy SubjectsNCT01406002Astellas Pharma Inc26
已完成
1 期
DDI Study Between Dorzagliatin and RifampicinDrug InteractionNCT04080609Hua Medicine Limited15